Sonrgy Secures Exclusive License to Commercialize Drug Delivery Nanotechnology
Sonrgy, Inc. recently announced it has entered into an exclusive license agreement with the University of California for the company’s core technology, an ultrasound-sensitive drug delivery platform.
The agreement grants the company the sole rights to develop and market the technology worldwide. Protecting the fundamental enabling technology establishes a significant barrier to potential competitors, and is a vital step toward bringing the platform to the clinic.
Based on research conducted in the lab of Prof. Sadik Esener at the UC San Diego Moores Cancer Center, “the SonRx technology addresses long-standing challenges related to stability and controlled release in nano-scale drug delivery,” stated Dr. Michael Benchimol, Sonrgy’s Chief Technology Officer. “We are excited to initiate the next steps of its commercial development.”
Sonrgy is a preclinical stage biotechnology company based in San Diego, CA, that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy’s tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focused beam of ultrasound.
These carriers deposit drugs directly at the tumor cell sites, avoiding the many serious side effects of toxic chemotherapy circulating in the blood stream. Nanocarriers can deliver chemotherapy before surgery to reduce tumor size, after surgery to prevent recurrence and in situations when surgery is not possible to arrest tumor growth. This distinctive approach to delivering chemotherapy can be applied to many cancer tumors and enables more intensive treatment of the cancer, potentially improving effectiveness while reducing harmful effects on the rest of the body. For more information, visit www.sonrgy.com.
Total Page Views: 888
